{"success":true,"data":{"pressRelease":{"id":"145058","rtpr_id":"nGNE3L8wHL-20260916","ticker":"TEVA","exchange":"","all_tickers":["TEVA"],"title":"Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care","author":"Globe Newswire","published_at":"2026-09-16T12:00:00.037Z","article_body":"* Long-acting injectables (LAIs) offer an opportunity to improve adherence and\npotential outcomes for patients with schizophrenia\n* LongActingImpact.com (http://www.LongActingImpact.com) is a new resource\ncenter designed to support clinicians in having informed treatment\nconversations with those living with schizophrenia\n* As a leader in neuroscience, Teva is committed to supporting clinicians by\nproviding evidence-based resources which could help improve schizophrenia care\nPARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) --\nTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.\n(NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com\n(https://www.globenewswire.com/Tracker?data=mSMyCIcc-3HKd-otd2xR2zNjC-AyJZOrX0oIoxOD_-A1-jhDynlUgYoDz3QaG-oOkvj5789efl1JN4zR9WV9qYJISkwjA6uOfB97WlTosWc=),\na new educational website for healthcare providers (HCPs) with information to\nsupport informed treatment discussions and decision-making around the role of\nlong-acting injectables (LAIs) in schizophrenia care. This bespoke resource is\nintended to equip clinicians with key information on LAI benefits and\npractical guidance for discussing LAIs with their patients.\n\nThe new resource provides HCPs with information focused on key topics,\nincluding:\n* How LAIs reduce relapse risk and protect patient outcomes\n* Strategies for ensuring consistent treatment delivery when patients struggle\nwith adherence to daily medication\n* How LAIs can support continuity of care, especially during the critical\ntransition from inpatient to outpatient settings\n* Step-by-step guidance for navigating patient conversations, from identifying\nlife goals to building trust through open, ongoing dialogue\nAccording to an analysis, 67% of patients taking oral medications for\nschizophrenia were nonadherent or stopped taking them altogether.(1)\nLong-acting treatment options, like LAIs, may help people challenged with\ntaking a daily medication. Despite this, LAIs remain underutilized due to\nperceived patient resistance and operational complexities.\n\n“Long-acting injectables can help address one of the most persistent\nchallenges in schizophrenia care – consistent medication adherence – but\ntheir potential cannot be fully realized if they are not considered as a\ntreatment option. We’ve heard from physicians that systemic hurdles, along\nwith the complexities of navigating treatment conversations, can create\nbarriers to care,” said Verena Ramirez Campos, VP of U.S. Medical Affairs\nand Global Innovative Strategy at Teva. “LongActingImpact.com is our\ncommitment to helping remove those barriers by empowering clinicians with the\nright resources to ensure that people living with schizophrenia have a better\nchance at a life free from relapse.”\n\nAn estimated 2.2 million people are currently diagnosed with schizophrenia in\nthe U.S.(2) Living with schizophrenia carries profound implications for a\nperson’s life and is linked to suboptimal long-term outcomes, with\nmedication adherence to daily oral options frequently presenting as a major\nimpediment to effective care.(3)\n\n“Many patients don’t hear about long-acting injectables until after\nthey’ve experienced repeated relapses or hospitalizations, even though they\nhave been part of schizophrenia care for years,” said Bryce Reynolds, MD at\nCarolina Outreach. “As clinicians, our role is to introduce these options\nearlier and use every available tool to integrate them into our practice and\nsupport more streamlined approaches to treatment.”\n\nAll resources are available online to any HCPs seeking information. To learn\nmore, visit www.LongActingImpact.com.\n\nAbout Teva\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into\na leading innovative biopharmaceutical company, enabled by a world-class\ngenerics business. For over 120 years, Teva’s commitment to bettering health\nhas never wavered. From innovating in the fields of neuroscience and\nimmunology to providing complex generic medicines, biosimilars and pharmacy\nbrands worldwide, Teva is dedicated to addressing patients’ needs, now and\nin the future. At Teva, We Are All In For Better Health. To learn more about\nhow, visit www.tevapharm.com.\n\nAbout Schizophrenia\nSchizophrenia is a chronic, progressive and severely debilitating mental\ndisorder that affects how one thinks, feels and acts.(4) Patients experience\nan array of symptoms, which may include delusions, hallucinations,\ndisorganized speech or behavior and impaired cognitive\nability.(4)(,)(5)(,)(6) Approximately 1% of the world’s population will\ndevelop schizophrenia in their lifetime, and 2.2 million people in the U.S.\nare currently diagnosed with the condition.(2,)(5)(,)(6) Although\nschizophrenia can occur at any age, the average age of onset tends to be in\nthe late teens to the early 20s for men, and the late 20s to early 30s for\nwomen.(4) The long-term course of schizophrenia is marked by episodes of\npartial or full remission broken by relapses that often occur in the context\nof psychiatric emergency and require hospitalization.(6) Approximately 80% of\npatients experience multiple relapses over the first five years of treatment,\nand each relapse carries a biological risk of loss of function, treatment\nrefractoriness, and changes in brain morphology.(7)(,)(8)(,)(9) Patients are\noften unaware of their illness and its consequences, contributing to treatment\nnonadherence, high discontinuation rates, and ultimately, significant direct\nand indirect healthcare costs from subsequent relapses and\nhospitalizations.(4)(,)(5)(,)(6)(,)(7)(,)(8)(,)(9) \n\nTeva Cautionary Note Regarding Forward Looking Statements\nThis Document may contain forward-looking statements within the meaning of the\nPrivate Securities Litigation Reform Act of 1995, which are based on\nmanagement’s current beliefs and expectations and are subject to substantial\nrisks and uncertainties, both known and unknown, that could cause our future\nresults, performance or achievements to differ significantly from that\nexpressed or implied by such forward-looking statements. You can identify\nthese forward-looking statements by the use of words such as “should,”\n“expect,” “anticipate,” “estimate,” “target,” “may,”\n“project,” “guidance,” “intend,” “plan,” “believe” and\nother words and terms of similar meaning and expression in connection with any\ndiscussion of future operating or financial performance. Important factors\nthat could cause or contribute to such differences include risks relating to:\nour ability to successfully develop and commercialize products for the\ntreatment of schizophrenia; the creation of LongActingImpact.com and it\nbecoming a new resource center designed to support clinicians in having\ninformed treatment conversations with those living with schizophrenia; our\nability to successfully compete in the marketplace, including our ability to\nsuccessfully execute on our Pivot to Growth strategy, including to expand our\ninnovative and biosimilar medicines pipeline and to profitably commercialize\nour innovative medicines and biosimilar portfolio, whether organically or\nthrough business development, to sustain and focus our portfolio of generic\nmedicines, and to execute on our organizational transformation and to achieve\nexpected cost savings; our significant indebtedness; our business and\noperations in general; compliance, regulatory and litigation matters; other\nfinancial and economic risks; and other factors discussed in our Quarterly\nReport on Form 10-Q for the second quarter of 2026 and in our Annual Report on\nForm 10-K for the year ended December 31, 2025, including in the sections\ncaptioned “Risk Factors” and “Forward Looking Statements.”\nForward-looking statements speak only as of the date on which they are made,\nand we assume no obligation to update or revise any forward-looking statements\nor other information contained herein, whether as a result of new information,\nfuture events or otherwise. You are cautioned not to put undue reliance on\nthese forward-looking statements.\n\nReferences:\n1. MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer J-P.\nPatterns of adherence to oral atypical antipsychotics among patients diagnosed\nwith schizophrenia. J Manag Care Spec Pharm. 2016;22(11):1349-1361\n2. DRG / Clarivate (Nov 2025 Market Forecast Assumptions-Schizophrenia)\n3. Mental illness - national institute of mental health (NIMH). National\nInstitute of Mental Health. (n.d.).\nhttps://www.nimh.nih.gov/health/statistics/mental-illness\n4. Substance Abuse and Mental Health Services Administration. Schizophrenia.\nhttps://www.samhsa.gov/mental-health/schizophrenia. Accessed March 2026.\n5. Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J\nClin Psychiatry. 2023;84(1):MS21078COM5.\nhttps://doi.org/10.4088/JCP.MS21078COM5.\n6. Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and\nReduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl),\nS62–S68. https://doi.org/10.37765/ajmc.2020.43013.\n7. Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of\npaliperidone palmitate injections in the management of patients with\nschizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14,\n205–223. \n8. Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse\nin schizophrenia. BMC Psychiatry 13, 50. \n9. Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity,\nand brain tissue loss in schizophrenia: a prospective longitudinal MRI\nstudy. The Am J Psychiatry, 170(6), 609–615. \nTeva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com\n\nTeva Investor Relations Inquiries: TevaIR@Tevapharm.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE3L8wHL-20260916","title":"Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care","author":"Globe Newswire","ticker":"TEVA","created":"2026-09-16T12:00:00.037Z","tickers":["TEVA"],"exchange":"","article_body":"* Long-acting injectables (LAIs) offer an opportunity to improve adherence and\npotential outcomes for patients with schizophrenia\n* LongActingImpact.com (http://www.LongActingImpact.com) is a new resource\ncenter designed to support clinicians in having informed treatment\nconversations with those living with schizophrenia\n* As a leader in neuroscience, Teva is committed to supporting clinicians by\nproviding evidence-based resources which could help improve schizophrenia care\nPARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) --\nTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.\n(NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com\n(https://www.globenewswire.com/Tracker?data=mSMyCIcc-3HKd-otd2xR2zNjC-AyJZOrX0oIoxOD_-A1-jhDynlUgYoDz3QaG-oOkvj5789efl1JN4zR9WV9qYJISkwjA6uOfB97WlTosWc=),\na new educational website for healthcare providers (HCPs) with information to\nsupport informed treatment discussions and decision-making around the role of\nlong-acting injectables (LAIs) in schizophrenia care. This bespoke resource is\nintended to equip clinicians with key information on LAI benefits and\npractical guidance for discussing LAIs with their patients.\n\nThe new resource provides HCPs with information focused on key topics,\nincluding:\n* How LAIs reduce relapse risk and protect patient outcomes\n* Strategies for ensuring consistent treatment delivery when patients struggle\nwith adherence to daily medication\n* How LAIs can support continuity of care, especially during the critical\ntransition from inpatient to outpatient settings\n* Step-by-step guidance for navigating patient conversations, from identifying\nlife goals to building trust through open, ongoing dialogue\nAccording to an analysis, 67% of patients taking oral medications for\nschizophrenia were nonadherent or stopped taking them altogether.(1)\nLong-acting treatment options, like LAIs, may help people challenged with\ntaking a daily medication. Despite this, LAIs remain underutilized due to\nperceived patient resistance and operational complexities.\n\n“Long-acting injectables can help address one of the most persistent\nchallenges in schizophrenia care – consistent medication adherence – but\ntheir potential cannot be fully realized if they are not considered as a\ntreatment option. We’ve heard from physicians that systemic hurdles, along\nwith the complexities of navigating treatment conversations, can create\nbarriers to care,” said Verena Ramirez Campos, VP of U.S. Medical Affairs\nand Global Innovative Strategy at Teva. “LongActingImpact.com is our\ncommitment to helping remove those barriers by empowering clinicians with the\nright resources to ensure that people living with schizophrenia have a better\nchance at a life free from relapse.”\n\nAn estimated 2.2 million people are currently diagnosed with schizophrenia in\nthe U.S.(2) Living with schizophrenia carries profound implications for a\nperson’s life and is linked to suboptimal long-term outcomes, with\nmedication adherence to daily oral options frequently presenting as a major\nimpediment to effective care.(3)\n\n“Many patients don’t hear about long-acting injectables until after\nthey’ve experienced repeated relapses or hospitalizations, even though they\nhave been part of schizophrenia care for years,” said Bryce Reynolds, MD at\nCarolina Outreach. “As clinicians, our role is to introduce these options\nearlier and use every available tool to integrate them into our practice and\nsupport more streamlined approaches to treatment.”\n\nAll resources are available online to any HCPs seeking information. To learn\nmore, visit www.LongActingImpact.com.\n\nAbout Teva\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into\na leading innovative biopharmaceutical company, enabled by a world-class\ngenerics business. For over 120 years, Teva’s commitment to bettering health\nhas never wavered. From innovating in the fields of neuroscience and\nimmunology to providing complex generic medicines, biosimilars and pharmacy\nbrands worldwide, Teva is dedicated to addressing patients’ needs, now and\nin the future. At Teva, We Are All In For Better Health. To learn more about\nhow, visit www.tevapharm.com.\n\nAbout Schizophrenia\nSchizophrenia is a chronic, progressive and severely debilitating mental\ndisorder that affects how one thinks, feels and acts.(4) Patients experience\nan array of symptoms, which may include delusions, hallucinations,\ndisorganized speech or behavior and impaired cognitive\nability.(4)(,)(5)(,)(6) Approximately 1% of the world’s population will\ndevelop schizophrenia in their lifetime, and 2.2 million people in the U.S.\nare currently diagnosed with the condition.(2,)(5)(,)(6) Although\nschizophrenia can occur at any age, the average age of onset tends to be in\nthe late teens to the early 20s for men, and the late 20s to early 30s for\nwomen.(4) The long-term course of schizophrenia is marked by episodes of\npartial or full remission broken by relapses that often occur in the context\nof psychiatric emergency and require hospitalization.(6) Approximately 80% of\npatients experience multiple relapses over the first five years of treatment,\nand each relapse carries a biological risk of loss of function, treatment\nrefractoriness, and changes in brain morphology.(7)(,)(8)(,)(9) Patients are\noften unaware of their illness and its consequences, contributing to treatment\nnonadherence, high discontinuation rates, and ultimately, significant direct\nand indirect healthcare costs from subsequent relapses and\nhospitalizations.(4)(,)(5)(,)(6)(,)(7)(,)(8)(,)(9) \n\nTeva Cautionary Note Regarding Forward Looking Statements\nThis Document may contain forward-looking statements within the meaning of the\nPrivate Securities Litigation Reform Act of 1995, which are based on\nmanagement’s current beliefs and expectations and are subject to substantial\nrisks and uncertainties, both known and unknown, that could cause our future\nresults, performance or achievements to differ significantly from that\nexpressed or implied by such forward-looking statements. You can identify\nthese forward-looking statements by the use of words such as “should,”\n“expect,” “anticipate,” “estimate,” “target,” “may,”\n“project,” “guidance,” “intend,” “plan,” “believe” and\nother words and terms of similar meaning and expression in connection with any\ndiscussion of future operating or financial performance. Important factors\nthat could cause or contribute to such differences include risks relating to:\nour ability to successfully develop and commercialize products for the\ntreatment of schizophrenia; the creation of LongActingImpact.com and it\nbecoming a new resource center designed to support clinicians in having\ninformed treatment conversations with those living with schizophrenia; our\nability to successfully compete in the marketplace, including our ability to\nsuccessfully execute on our Pivot to Growth strategy, including to expand our\ninnovative and biosimilar medicines pipeline and to profitably commercialize\nour innovative medicines and biosimilar portfolio, whether organically or\nthrough business development, to sustain and focus our portfolio of generic\nmedicines, and to execute on our organizational transformation and to achieve\nexpected cost savings; our significant indebtedness; our business and\noperations in general; compliance, regulatory and litigation matters; other\nfinancial and economic risks; and other factors discussed in our Quarterly\nReport on Form 10-Q for the second quarter of 2026 and in our Annual Report on\nForm 10-K for the year ended December 31, 2025, including in the sections\ncaptioned “Risk Factors” and “Forward Looking Statements.”\nForward-looking statements speak only as of the date on which they are made,\nand we assume no obligation to update or revise any forward-looking statements\nor other information contained herein, whether as a result of new information,\nfuture events or otherwise. You are cautioned not to put undue reliance on\nthese forward-looking statements.\n\nReferences:\n1. MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer J-P.\nPatterns of adherence to oral atypical antipsychotics among patients diagnosed\nwith schizophrenia. J Manag Care Spec Pharm. 2016;22(11):1349-1361\n2. DRG / Clarivate (Nov 2025 Market Forecast Assumptions-Schizophrenia)\n3. Mental illness - national institute of mental health (NIMH). National\nInstitute of Mental Health. (n.d.).\nhttps://www.nimh.nih.gov/health/statistics/mental-illness\n4. Substance Abuse and Mental Health Services Administration. Schizophrenia.\nhttps://www.samhsa.gov/mental-health/schizophrenia. Accessed March 2026.\n5. Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J\nClin Psychiatry. 2023;84(1):MS21078COM5.\nhttps://doi.org/10.4088/JCP.MS21078COM5.\n6. Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and\nReduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl),\nS62–S68. https://doi.org/10.37765/ajmc.2020.43013.\n7. Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of\npaliperidone palmitate injections in the management of patients with\nschizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14,\n205–223. \n8. Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse\nin schizophrenia. BMC Psychiatry 13, 50. \n9. Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity,\nand brain tissue loss in schizophrenia: a prospective longitudinal MRI\nstudy. The Am J Psychiatry, 170(6), 609–615. \nTeva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com\n\nTeva Investor Relations Inquiries: TevaIR@Tevapharm.com"},"type":"article","timestamp":"2026-09-16T12:00:00.182604398Z","server_sent_at_ms":1789560000182},"received_at":"2026-09-16T12:00:00.241Z","source_url":null},"analysis":{"id":"133901","press_release_id":"145058","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["Promotional/educational content with no new clinical trial data and no specific Teva LAI product named — low-information release"],"eventType":"product_launch","narrative":"Teva's U.S. affiliate launched LongActingImpact.com, a new educational website for healthcare providers on the role of long-acting injectables (LAIs) in schizophrenia care.\n\nThe resource focuses on adherence gaps: an analysis cited in the release found 67% of patients on oral schizophrenia medications were nonadherent or stopped treatment, and roughly 2.2 million people in the U.S. are diagnosed with schizophrenia.\n\nThe launch is a medical-affairs and awareness initiative supporting Teva's neuroscience positioning under its Pivot to Growth strategy, with no new clinical data, product approvals, or financial disclosures.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Clinician-education platform around LAIs reads as early commercial groundwork for Teva's schizophrenia franchise, but carries no near-term financial impact."},"keyFigures":{"customDimensions":{"oral_nonadherence_rate":"67%","multiple_relapse_rate_first_5_years":"80%","us_diagnosed_schizophrenia_patients":"2.2 million"}},"quotedText":"Long-acting injectables can help address one of the most persistent\nchallenges in schizophrenia care – consistent medication adherence – but\ntheir potential cannot be fully realized if they are not considered as a\ntreatment option.","namedEntities":{"people":[{"name":"Verena Ramirez Campos","role":"VP of U.S. Medical Affairs and Global Innovative Strategy at Teva"},{"name":"Bryce Reynolds, MD","role":"clinician at Carolina Outreach"}],"products":["LongActingImpact.com","long-acting injectables (LAIs)"],"companies":[{"name":"Teva Pharmaceutical Industries Ltd.","ticker":"TEVA","relationship":"filer"},{"name":"Teva Pharmaceuticals","relationship":"U.S. affiliate of the filer"},{"name":"Carolina Outreach","relationship":"clinician organization quoted in release"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Launch of an educational website for clinicians is a medical-affairs/awareness initiative with no new clinical data, regulatory action, or financial figures disclosed. Routine corporate communications with negligible near-term financial impact."},"tickerRelevance":{"others":[],"primary":"TEVA"},"globalImportance":12,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap pharma","eventGravity":"educational website launch / medical affairs initiative","issuerAuthored":true,"householdBrandBoost":"moderate","financialMateriality":"none disclosed"}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Teva's U.S. affiliate launched LongActingImpact.com, a new educational website for healthcare providers on the role of long-acting injectables (LAIs) in schizophrenia care.\n\nThe resource focuses on adherence gaps: an analysis cited in the release found 67% of patients on oral schizophrenia medications were nonadherent or stopped treatment, and roughly 2.2 million people in the U.S. are diagnosed with schizophrenia.\n\nThe launch is a medical-affairs and awareness initiative supporting Teva's neuroscience positioning under its Pivot to Growth strategy, with no new clinical data, product approvals, or financial disclosures.","key_figures":{"customDimensions":{"oral_nonadherence_rate":"67%","multiple_relapse_rate_first_5_years":"80%","us_diagnosed_schizophrenia_patients":"2.2 million"}},"named_entities":{"people":[{"name":"Verena Ramirez Campos","role":"VP of U.S. Medical Affairs and Global Innovative Strategy at Teva"},{"name":"Bryce Reynolds, MD","role":"clinician at Carolina Outreach"}],"products":["LongActingImpact.com","long-acting injectables (LAIs)"],"companies":[{"name":"Teva Pharmaceutical Industries Ltd.","ticker":"TEVA","relationship":"filer"},{"name":"Teva Pharmaceuticals","relationship":"U.S. affiliate of the filer"},{"name":"Carolina Outreach","relationship":"clinician organization quoted in release"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T12:00:45.287Z","global_importance":12,"audience_relevance":20,"importance_components":{"tickerTier":"large-cap pharma","eventGravity":"educational website launch / medical affairs initiative","issuerAuthored":true,"householdBrandBoost":"moderate","financialMateriality":"none disclosed"}},"durationMs":45038,"modelName":"glm-5.3-flash"}}